Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

NextEdge Admin

03 Feb 2025

2 min 33 sec

Metropolis Healthcare Limited recently announced a partnership with Roche Diagnostics India and Neighbouring Markets to introduce a self-sampling human papillomavirus (HPV) DNA test for cervical cancer screening. The test aims to improve access to early cervical cancer detection across India, particularly in Tier 2, Tier 3, and Tier 4 towns, addressing both social and economic barriers to screening.

Cervical cancer is preventable, yet India accounts for 21% of the world’s cervical cancer cases, with nearly 79,000 deaths annually. The high mortality rate is often due to late-stage diagnosis, which could be avoided through early screening. The introduction of the HPV DNA test, recognized by the World Health Organization (WHO) as the first-choice screening method, provides a clinically validated, FDA-approved, and WHO-prequalified solution. This test detects 14 high-risk HPV types in a single sample, ensuring accurate and reliable results for better early intervention.

Surendran Chemmenkotil, CEO of Metropolis Healthcare, emphasized the company’s commitment to expanding access to early cervical cancer detection through their extensive laboratory network and partnerships with hospitals. The collaboration with Roche aims to create a future where cervical cancer is no longer a major health threat.

The self-sampling HPV DNA test enables women to collect their own samples comfortably, addressing barriers such as stigma and limited access to healthcare facilities. Currently, only about 1.9% of Indian women undergo screening, as per a 2020 NHFS survey. Rishubh Gupta, Managing Director of Roche Diagnostics India, expressed confidence that the test’s introduction, along with Metropolis’s established laboratory presence, would significantly increase screening rates, particularly in underserved areas.